C4 Therapeutics vs Monte Rosa Therapeutics
CCCC and GLUE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CCCC and GLUE compare
Monte Rosa Therapeutics is the larger company, worth 2.5 times as much as C4 Therapeutics ($880M against $356M).
C4 Therapeutics grew revenue faster over the last twelve months (7.2% versus −61.3% for Monte Rosa Therapeutics).
Monte Rosa Therapeutics keeps more of each dollar of sales as profit, with a net margin of −186% compared with −282% at C4 Therapeutics.
C4 Therapeutics scores higher on the StockData Score (8 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CCCC | GLUE |
|---|---|---|
| Size and price | ||
| Market cap | $356M | $880M |
| Share price | $2.89 | $10.31 |
| Change, 1 year | 23.5% | −26.7% |
| Change, 5 years | −92.5% | −47.3% |
| Beta (5Y) | 2.52 | 1.85 |
| Employees | 104 | 150 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.0× (better) | 12.5× |
| P/B | 1.6× (better) | 1.8× |
| FCF yield | −22.4% | −19.8% (better) |
| Fair value | $2.43 | $8.68 |
| Margin of safety | −18.7% (better) | −18.8% |
| Growth | ||
| Revenue growth (TTM) | 7.2% (better) | −61.3% |
| Net income growth (TTM) | – | −725% |
| EPS growth (TTM) | – | −660% |
| Profitability | ||
| Operating margin | −316% | −214% (better) |
| Net margin | −282% | −186% (better) |
| FCF margin | −247% (better) | −248% |
| Return on equity | −47.6% | −35.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.17 | 10.32 (better) |
| Altman Z-score | −1.65 | 1.87 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.07% | – |
| Shareholder yield | 0.07% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 95.6% | 109% |
| Held by insiders | 2.8% | 11.5% |
| Insider net buying, 12 months | −$22.2K (better) | −$4.1M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 38.9% | 27.6% |
Go deeper
- CCCC stock overview
- CCCC income statement
- CCCC valuation and score
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.